Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) Fighting ED with Stem Cells

386

 

Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) is a commercial stage biotechnology company, and certainly represents the first time we’ve taken a look at a company on a mission to combat erectile dysfunction. It’s a rather serious problem of varying severity that affects tens of millions of men. CELZ does it with its flagship patented process, CaverStem™.

CaverStem™ involves extraction of a small amount of bone marrow from the patient, separating stem cells from the bone marrow using an FDA cleared device, followed by re-administration of the stem cells into the corpus cavernosa of the patient’s penis. Two clinical studies have been conducted utilizing patient’s own bone marrow stem cells administered into the penis, which demonstrated safety and signals of efficacy.

Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) will actually be exhibiting its patented CaverStemTM stem cell procedure for erectile dysfunction at the annual American Urological Association (AUA) conference on May 18-21, 2018 in San Francisco.

According to the AUA “Last year’s meeting welcomed more than 16,000 attendees from more than 100 countries around the world, underscoring the meeting’s value to the global urologic community. This year’s meeting will feature more innovative programming and educational offerings than ever before, giving physicians unparalleled access to groundbreaking research, the latest clinical guidelines and the most advanced technologies in urology.” (aua.org)

“Our cutting edge technology in autologous stem cell treatment for erectile dysfunction is anticipated to be received by the urologic community with great enthusiasm as our CaverStem TM procedure represents an all-natural alternative for those patients resistant to the use of PDE5 inhibitors such as Viagra and Cialis,” said Thomas Ichim PhD, Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.

According to multiple publications, approximately 30% of the 30,000,000 men suffering from erectile dysfunction are resistant to such PDE5 inhibitors.

“Since beginning commercialization of our patented and tested CaverStemTM procedure in November 2017, we have received positive responses from the urology community in the limited cities marketed. We anticipate the introduction of our technology to the attendees of the largest annual urology conference, to promote nationwide interest in CaverStemTM,” said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc. (Source: PR Newswire)

CELZ is also using stem cells to fight other disorders as well, having recently announced the formation of CerebroStem LLC, a majority owned subsidiary focused on developing stem cell therapies for brain injuries and neurodegenerative diseases. The Company’s initial focus will be treating radiation induced brain damage, a major cause of cognitive dysfunction in patients with brain cancer who have received radiation therapy.

 

“The AmnioStem™ amniotic stem cell product offers a potent platform for developing second generation stem cell therapies useful for neurodegenerative and other neurological diseases,” said Santosh Kesari, MD, Ph.D, FANA, FAAN, Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-Oncology, Providence Saint John’s Health Center, who leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute. “I am enthusiastic to combine new treatments and procedures developed by AmnioStem™ universal donor cell therapy, which I believe will allow for rapid clinical entry.”

Dr. Kesari will serve as the Chief Medical Advisor for CerebroStem LLC.  In addition to treating radiation induced brain damage, CerebroStem LLC plans to pursue other areas of brain degeneration including stroke, multiple sclerosis, and Parkinson’s Disease.  (Source: PR Newswire)

Meanwhile, the CELZ chart has been experiencing bullishness in recent sessions, and the massive amount of volume influx is what initially drew us to this play in the first place. We’ll be sure to keep an eye on it from here on out. We’ll stay up on any further developments with CELZ and pass them along to you! Stay locked on StreetRegister.com and be sure you’re signed up for our 100% free smallcap newsletter. It’s as easy as that! Simply submit your primary active email address in the box below. Subscribe now!

   Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in CELZ stock, short or long.

 

 

LEAVE A REPLY